In 2005, the Federal Drug Administration approved Byetta, the first glucagon-like peptide-1 receptor agonist drug, to treat Type 2 diabetes
Calcif Tissue Int 107:281293 Lv F, Cai X, Lin C, Yang W, Ji L (2024) Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice
The amount you can receive from a Zepbound lawsuit can vary greatly depending on the specifics and strength of the case
I can only speak to my own experience: with MCAS and its many comorbidities, I have always been medication sensitive, and that sensitivity seems, in this case, to be working in my favour
Do GLP-1 agonists boost mood and memory